8-K: Cassava Shifts Focus to TSC Epilepsy, Reports Q2 Loss

Cassava Sciences reported a Q2 2025 net loss of $44.2 million, shifting its development focus to simufilam for TSC-related epilepsy with a clinical study planned for H1 2026, and recorded a $31.25 million litigation loss contingency.

Summary

• Reported a net loss of $44.2 million for the second quarter ended June 30, 2025, compared to a net income of $6.2 million for the same period in 2024.
• Shifted development focus to simufilam as a potential treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy.
• Positive preclinical results for simufilam in a mouse model of TSC-related epilepsy, showing a 60% reduction in seizure frequency compared to vehicle.
• A proof-of-concept clinical study for TSC-related epilepsy is planned to begin in H1 2026.
• Recorded a $31.25 million estimated loss contingency in Q2 2025 related to the potential settlement of certain securities litigation.
• Cash and cash equivalents totaled $112.4 million as of June 30, 2025, with no debt.
• Net cash used in operations was $16.3 million during the first half of 2025.
• Expected net cash use in operations for the second half of 2025 is $47 to $51 million, including the $31.25 million litigation contingency.
• Estimated cash at year-end 2025 is projected to be in a range from $61 to $65 million.
• Research and development (R&D) expenses decreased by 66% to $5.1 million in Q2 2025, primarily due to the phase out of the Alzheimer's disease development program.
• General and administrative (G&A) expenses were $40.3 million in Q2 2025, a 13% decrease from Q2 2024, mainly due to a lower litigation contingency compared to the prior year.
• Appointed Dr. Joseph Hulihan as Chief Medical Officer, Dr. Anglique Bordey as Senior Vice President, Neuroscience, and Dr. Jack Moore as Senior Vice President, Clinical Development.

Sentiment

Score: 4

Explanation: The company is pivoting to a new, promising rare disease indication with positive preclinical data and new leadership, which is a positive. However, the significant net loss, the large litigation contingency, and the substantial projected cash burn for the remainder of the year, coupled with the abandonment of the Alzheimer's program, introduce considerable financial and strategic uncertainty.

Positives

• Positive preclinical data for simufilam in TSC-related epilepsy, demonstrating a 60% reduction in seizure frequency in a mouse model, supporting its potential as a novel, first-in-class treatment.
• Initiated a new program focused on TSC-related epilepsy, a rare disease with significant unmet medical needs, potentially offering a clearer development path.
• Strengthened leadership team with the appointment of experienced neuroscience professionals, including a Chief Medical Officer with expertise in neurotherapeutics and epilepsy.
• Maintained a solid cash and cash equivalents balance of $112.4 million as of June 30, 2025, with no debt.
• Significant reduction in R&D expenses (66% decrease) due to the completion of the Alzheimer's disease development program, allowing for focused resource allocation on the new program.

Negatives

• Reported a substantial net loss of $44.2 million in Q2 2025, a significant decline from the net income of $6.2 million in the same period of 2024.
• Recorded a $31.25 million estimated loss contingency in Q2 2025 for the potential settlement of certain securities litigation, indicating ongoing legal challenges and a significant financial drain.
• Projected a substantial net cash use of $47 to $51 million in the second half of 2025, which is expected to reduce year-end cash to $61 to $65 million.
• The net income reported in 2024 was primarily due to a non-cash gain from the change in fair value of warrant liabilities, not from operational profitability.
• The shift from the Alzheimer's disease program, previously a major focus, to a new indication may signal a setback or re-prioritization of their lead asset.

Risks

• Ability to advance preclinical studies related to TSC-related epilepsy and other potential indications.
• Ability to successfully carry out the Company's obligations under the Yale License Agreement.
• Ability to initiate an initial proof-of-concept study of simufilam in TSC-related epilepsy.
• Inherent risks in drug discovery and development, which is a long, complex, costly, and high-risk process.
• Clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval.
• The safety, efficacy, or other desirable attributes of investigational product candidates have not been established in any patient population.
• Uncertainty regarding the potential resolution of the certain securities litigation and the accuracy of loss contingency estimates related thereto.
• Potential for total loss of investment due to the fundamental risks associated with drug discovery and development.

Future Outlook

The company plans to initiate a proof-of-concept clinical study for simufilam in TSC-related epilepsy in the first half of 2026, following positive preclinical data. They anticipate net cash use of $47 to $51 million in the second half of 2025, projecting a year-end cash balance between $61 and $65 million.

Management Comments

• "2025 has been transformational for Cassava. We have initiated a new program focused on TSC-related epilepsy, a rare disease for which patients urgently need more treatment options." Rick Barry, President and Chief Executive Officer.
• "Two encouraging animal model studies—one conducted at Yale and another with the TSC Alliance—support the exploration of simufilam as a novel, first-in-class approach to this disease." Rick Barry, President and Chief Executive Officer.

Industry Context

The company's strategic pivot to Tuberous Sclerosis Complex (TSC)-related epilepsy positions it within the rare disease therapeutic area, which often benefits from specific regulatory pathways and high unmet medical needs. This shift also marks a departure from the highly scrutinized and competitive Alzheimer's disease drug development landscape. The appointment of key neuroscience leaders aligns with industry practices for building expertise around a new therapeutic focus.

Comparison to Industry Standards

• The preclinical data showing a 60% reduction in seizure frequency in a mouse model for TSC-related epilepsy represents a strong initial signal, comparable to promising early-stage results seen in other rare neurological disorder drug development programs.
• Focusing on a rare disease like TSC-related epilepsy, which affects approximately 50,000 people in the US and has a high unmet need for effective treatments, aligns with a common biotech strategy to target smaller, underserved patient populations where drug development can be more streamlined and market access potentially more favorable.
• The cash position of $112.4 million, with a projected decline to $61-$65 million by year-end, is within the typical range for a clinical-stage biotechnology company, though the significant legal contingency adds an unusual financial burden compared to peers solely focused on R&D.
• The appointment of a Chief Medical Officer with specific expertise in epilepsy and Senior Vice Presidents for Neuroscience and Clinical Development is a standard and positive move for a company initiating a new clinical program in a specialized area.

Management Changes

Legal Proceedings

• Advanced settlement negotiations are ongoing to resolve certain securities litigation.
• Recorded a $31.25 million estimated loss contingency in Q2 2025 related to the potential settlement of certain securities litigation.
• A $40.0 million SEC-related loss contingency was recorded in 2024, contributing to the decrease in G&A expenses in Q2 2025 compared to Q2 2024.

Stakeholder Impact

• Shareholders face increased financial uncertainty due to the significant net loss, the large litigation contingency, and the projected substantial cash burn, which could impact share price and potentially lead to future dilution if capital raises are needed.
• Patients with TSC-related epilepsy may benefit from a potential novel treatment option if simufilam successfully progresses through clinical development.
• Employees may experience a renewed strategic focus with the shift to a new indication and the appointment of new leadership, though the financial situation warrants careful monitoring.
• Creditors are positively impacted by the company's reported lack of debt.

Next Steps

• Present data and analyses from the TSC-related epilepsy preclinical study in an upcoming scientific conference and publication.
• Conduct final pre-IND (Investigational New Drug) studies for simufilam in TSC-related epilepsy.
• Develop the regulatory strategy for simufilam in TSC-related epilepsy.
• Initiate a proof-of-concept clinical study for simufilam in TSC-related epilepsy in H1 2026.

Key Dates

Recommendation

While the pivot to TSC-related epilepsy with promising preclinical data and new leadership offers a potential new path for Cassava Sciences, the significant net loss, the substantial cash burn projected for H2 2025, and the ongoing legal liabilities (evidenced by the $31.25 million contingency) create considerable financial uncertainty. The company is still in early-stage clinical development for its new focus, meaning high risk and a long path to potential commercialization. Investors should hold to observe the progress of the TSC-related epilepsy program and the resolution of legal matters before making further investment decisions.

Keywords

Cassava Sciences, SAVA, biotechnology, CNS disorders, Tuberous Sclerosis Complex, TSC-related epilepsy, simufilam, preclinical data, clinical study, Q2 2025 financials, net loss, cash, securities litigation, drug development, rare disease, neurotherapeutics, epilepsy